TPM1 and TPM2 are both members of tropomyosin (TPM) family, which discovered as a category of actin binding proteins acting as inhibitors of cellular transformation.36 Previous research reported that overexpression of TPM1 was related to a larger tumor size and a higher tumor grade, and TPM1 was proved as a potential biomarker of renal cell carcinoma prognosis.37 Unlike TPM1, poorly TPM2 were identified associated with malignant progression prostate tumors.38 As filtrated MDGs, whether TPM1 and TPM2 interact in the malignant progression of bladder cancer remains further study. The gene discussed is TPM2; the disease is prostate neoplasm.